DIABETIC NEUROPATHY: INNOVATIVE TREATMENT TECHNIQUES

Mihaela Alina Calin[1], Ana Magdalena Bratu[2]*, Adrian Petru Radu[2]*, Burduloi Vlăduț Mirel [3] Camelia Ana Grigore[1], Cristian Iorga[2], Cristina Raluca Iorga[2]

[1]"Dunarea De Jos" University of Galati, Faculty of Medicine, 47 Domneasca Str., 800008, Galati, Romania
[2]"Carol Davila" University of Medicine and Pharmacy, Dionisie Lupu Street no. 37, Sector 2, Bucharest, 020021, Romania
[3]"Grigore.T.Popa" University of Medicine and Pharmacy, Iasi, Romania, Department of Morphofunctional Sciences I. Department of Anatomy
*Corresponding authors: anaconstm@gmail.com, drradupetru@yahoo.com
All authors have the same contribution.

Abstract
Diabetic neuropathy represents a frequent and debilitating complication of diabetes, affecting the peripheral nervous system and contributing to symptoms such as pain, tingling, and numbness. In this review, we explore innovative treatment techniques that have been studied to alleviate the symptoms of diabetic neuropathy. Key aspects covered include low-level laser therapy (LLLT), transcutaneous electrical nerve stimulation (TENS), the use of antiepileptic and antidepressant medications, stem cell therapy, and the integration of virtual reality in pain therapy. LLLT has shown promise in stimulating nerve regeneration, while TENS provides a non-invasive approach to managing neuropathic pain. Antiepileptic and antidepressant medications have demonstrated significant benefits, and stem cell therapy is at the forefront of research for tissue regeneration. Additionally, the integration of virtual reality in pain therapy offers an innovative perspective, distracting patients from their symptoms and improving their quality of life. Managing diabetic neuropathy extends beyond conventional therapies, evolving constantly through the integration of innovative techniques with the potential to significantly enhance the quality of life for affected patients. It is essential to continue research and rigorously evaluate the effectiveness of these approaches, collaborating with healthcare professionals to provide personalized and efficient solutions.

Keywords: diabetic neuropathy; laser therapy (LLLT), TENS electrical stimulation

1. Introduction

Diabetic neuropathy (DN) is a common and serious complication of diabetes mellitus, affecting the peripheral nervous system. This condition results from nerve damage due to elevated blood glucose levels associated with diabetes. With a significant impact on the quality of life, diabetic neuropathy can influence various aspects of patients' physical and psychological health.[1,2]

It is characterized by nerve lesions that can affect various parts of the peripheral nervous system. These lesions can occur in different regions of the body, but most commonly affect the lower and upper extremities. Symptoms include pain, tingling, numbness, and muscle weakness, significantly impacting mobility and quality of life.[1-3]

The prevalence of diabetic neuropathy is on the rise, reflecting the global expansion of the diabetes mellitus epidemic. Studies show that approximately half of patients with diabetes develop diabetic neuropathy at some point in the course of their disease. This high prevalence underscores the importance of addressing diabetic neuropathy as a significant public health issue.[2,3]

Diabetic neuropathy significantly influences the quality of life of patients, with consequences on both physical and psychosocial aspects. Persistent pain and physical discomfort can lead to difficulties in performing daily activities, affecting overall functionality. Additionally, the psychological impact of chronic pain and disrupted sleep quality may contribute to stress, anxiety, and depression.[1,2]

Approaching diabetic neuropathy requires a profound understanding of the factors contributing to its onset and progression, as well as the impact it has on patients' lives. By exploring innovative

treatment and management techniques, there is hope for providing personalized solutions to enhance the quality of life for patients affected by this complex condition.[2-4]



Image 1. Complications and Management of Neuropathy [1]

2. Causes and mechanisms

The causes and mechanisms of diabetic neuropathy are complex and involve a series of pathological processes. Diabetes affects the peripheral nerves through several mechanisms, and understanding these is essential for the effective management and treatment of diabetic neuropathy.[4,5]



Image 2. Mechanisms of neuropathic diabetes[4]

2.1 Advanced glycosylation:

In the context of diabetes, elevated blood glucose levels can lead to a phenomenon known as advanced glycation. This involves the excessive binding of glucose molecules to proteins in the nerves, causing structural and functional changes in these proteins.[4-6]

2.2 Oxidative Stress:

Elevated glucose levels can trigger oxidative stress in nerves. This involves the excessive production of free radicals, which can cause cellular damage and nerve deterioration.[5,6]

2.3 Inflammation:

Diabetes can induce a chronic inflammatory response in the body. Inflammation affects the nerves and may contribute to their damage and disfunction.[4-6]

2.4 Insufficient Blood Flow:

Diabetes can affect the blood vessels that supply oxygen and nutrients to the nerves. Insufficient blood flow can lead to ischemia and inadequate supply to the nerves.[5-7]

2.5. Metabolic Imbalances:

Disruptions in glucose and lipid metabolism associated with diabetes can affect the normal functioning of nerves. These imbalances can influence how nerves transmit signals and respond to stimuli.[6,7]

2.6. Genetic Factors:

There is a genetic component to the predisposition to diabetic neuropathy. Certain individuals may have an increased susceptibility to nerve damage in diabetic conditions.[5,6]

2.7. Activation of Molecular Pathways:

Certain molecular pathways, such as the nerve growth factor (NGF) signaling pathways and protein kinase C (PKC) pathways, are implicated in the development of diabetic neuropathy.[5,6]

2.8. Cumulative Damage:

As these mechanisms act together over time, there is cumulative damage to the peripheral nerves, clinically manifested by the specific symptoms of diabetic neuropathy.[7]

3. Symptoms of diabetic neuropathy:

Pain: patients may experience persistent pain, burning, or a tingling sensation in the affected areas, usually in the feet and hands. The pain can be constant or occur in the form of episodes.[7,8]

Numbness and Tingling: feelings of numbness or tingling, often in the fingers or other parts of the limbs, can be signs of diabetic neuropathy.[8,9]

Muscle Weakness: muscular function may be affected, leading to weakness and difficulties in mobility.[8,9]

Balance and Coordination Issues: patients may have difficulties maintaining balance and coordination, increasing the risk of falls.[8,9]

Reduced Sensitivity to Pain and Temperature: sometimes, patients may develop reduced sensitivity to pain and temperature, which can lead to unnoticed injuries.[8-10]

Sexual Disfunction: diabetic neuropathy can affect the nerves controlling sexual functions, leading to erectile problems or sexual disfunction in women.[8,9]

4. Diagnosis of diabetic neuropathy

Image 3 Tests to diagnose neuropathy[10]

4.1 Anamnesis and Physical Examination
The doctor will discuss the patient's symptoms and conduct a physical examination to assess sensations, reflexes, muscle functions, and balance.[10-12]

4.2 Neuropathy Testing:
Nerve function tests may include reflex testing, tests of sensitivity to touch and temperature sensations, as well as electromyographic (EMG) tests to assess the electrical activity of muscles.[10,12]

4.3 Blood Sugar Measurement:
Controlling blood glucose levels is crucial for diagnosing and managing diabetic neuropathy. Strict blood sugar control may slow the progression of neuropathy.[11,12]

4.4 Nerve Biopsy:
In certain cases, the doctor may recommend a biopsy of a small nerve to evaluate nerve damage.[10,11]

4.5 Medical Imaging:
Imaging, such as MRI or CT scans, may be used to rule out other causes of symptoms, such as nerve compressions.[10-12]

4.6 Quality of Life Assessment Questionnaires:
Some standardized questionnaires may be used to assess the impact of neuropathy on the patient's quality of life.[10,12]

5. Conventional Treatment Methods for Diabetic Neuropathy

5.1 Control of Blood Sugar:
Maintaining blood glucose levels within recommended ranges can help prevent and slow the progression of diabetic neuropathy. Regular blood sugar monitoring and adjustments to diet and medication are essential.[13,14]

5.2 Antiepileptic Medications:
Medications such as gabapentin and pregabalin can help manage neuropathic pain. They work by stabilizing nerve activity and reducing painful sensations.[14,15]

5.3 Antidepressant Medications:
Certain antidepressants, such as amitriptyline and duloxetine, may be prescribed to treat neuropathic pain and improve mood. These medications have analgesic effects and can contribute to alleviating symptoms of associated depression.[13-15]

5.3 Pain Relievers:
Pain relievers, such as acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs), can be used to manage mild to moderate pain associated with diabetic neuropathy.[13,14, 26-31]

5.4 Physical and Occupational Therapy:
A regular exercise program can improve blood circulation, flexibility, and muscle strength. Physical and occupational therapists can provide guidance for individually adapted exercises and pain management techniques.[14,15,48,49, 32-36]

5.5 Risk Factor Control:
Quitting smoking and limiting alcohol consumption can contribute to managing diabetic neuropathy. These habits can worsen symptoms and impede the healing process.[15,16, 37-47]

5.6 Weight and Cholesterol Management:
Maintaining a healthy weight and managing cholesterol levels can help reduce pressure on the nervous system and improve overall health.[15-17]

5.7 Topical Treatment:
Some patients may benefit from the topical application of creams or gels containing substances such as capsaicin or lidocaine to alleviate painful sensations.[15,17]

5.8 Nutritional Interventions:
Nutritional supplements, such as vitamin B12 and omega-3 fatty acids, may be recommended to support nerve health.[16,17]

5.9 Assistive Devices:
Orthopedic footwear or assistive devices, such as compression stockings, can help reduce pressure on the feet and improve blood circulation.[15-17]

6. Innovative Treatment Techniques for Diabetic Neuropathy

6.1 Low Intensity Laser Light Therapy (LLLT)
Mechanism of Action: LLLT utilizes low-level light to stimulate mitochondria and improve cellular function. It is believed to help reduce inflammation and promote nerve regeneration.[18-20]
Clinical Evidence: studies have shown a significant improvement in symptoms of diabetic neuropathy, including pain reduction and improved nerve function. However, more research is needed to establish long-term effectiveness.[18,20]

6.2 Transcutaneous Electrical Nerve Stimulation (TENS):
Mechanism of Action: TENS uses electrical impulses to block the transmission of painful signals to the brain and stimulate the release of endorphins, thereby reducing the perception of pain.[19,21]
Clinical Evidence: studies have highlighted significant benefits in reducing neuropathic pain, making it a non-invasive therapeutic option with a low risk of side effects.[19-21]

6.3 Stem Cell Therapy:
Mechanism of Action: stem cell therapy involves the injection of stem cells into affected areas to stimulate nerve regeneration and improve their function.[19-21]
Clinical Evidence: preclinical studies and early clinical trials have indicated potential efficacy in nerve regeneration, but further research is needed to assess long-term safety and effectiveness.[19,21]

6.4 Virtual Reality in Pain Therapy:
Mechanism of Action: the use of virtual reality to distract patients from neuropathic pain and reduce its perception through visual and sensory stimuli.[19,20]
Clinical Evidence: in preliminary studies, virtual reality has shown promise in alleviating pain and stress associated with diabetic neuropathy, offering an innovative and well-tolerated approach.[19,20]

6.5 Neuroprotective Medications:
Mechanism of Action: the development of medications aimed at protecting nerves and preventing the progression of nerve damage.[19-21]
Clinical Evidence: research is ongoing to identify and test neuroprotective medications, with a focus on substances that can positively influence nerve function.[19-21]

6.6 Gene Editing Techniques:
Mechanism of Action: research in gene editing aims to correct genes involved in diabetic neuropathy to prevent or reverse nerve damage.[20,21]
Development Stage: in its early stages, this approach represents a promising perspective but requires further research to evaluate safety and effectiveness.[20,21]

7. Future Perspectives and Research Directions in the Treatment of Diabetic Neuropathy



Imagine 4 Nanotherapy[22]

7.1 Gene Editing and Gene Therapy:

Mechanism: development of precise gene editing techniques to correct genetic mutations associated with diabetic neuropathy. Gene therapy could provide a personalized approach to treating the genetic causes of neuropathy.[21-23]

7.2 Enhanced Stem Cell Therapy:

Mechanism: refinement of stem cell therapy techniques to enhance their effectiveness and safety in the treatment of diabetic neuropathy. Identifying optimal sources of stem cells and optimizing the administration protocol are key aspects.[22,23]

7.3 Nanotherapy for Drug Delivery:

Mechanism: development of nanomaterials and nanotechnologies for precise and efficient drug delivery to areas affected by diabetic neuropathy. This could enable controlled drug release with reduced effects on other organs.[22,23]

7.4 Monoclonal Antibody Therapy:

Mechanism: use of monoclonal antibodies to specifically target inflammatory factors and molecules involved in the progression of diabetic neuropathy. This approach could reduce inflammation and nerve damage associated with neuropathy.[22-24]

7.5 Integration of Brain Stimulation Technologies:

Mechanism: exploration of the use of brain stimulation technologies, such as deep brain stimulation, to modulate nerve signals and reduce pain perception in diabetic neuropathy.[22,25]

7.6 Innovations in Light Therapy:

Mechanism: development of advanced light therapy technologies, such as high-power lasers and photodynamic therapy, to achieve stronger effects in stimulating nerve regeneration and reducing inflammation.[23-25]

7.7 Artificial Intelligence in Diagnosis and Treatment:

Mechanism: utilization of artificial intelligence technologies for the analysis and interpretation of complex data associated with diabetic neuropathy. This could contribute to the development of faster diagnostic methods and personalized treatment plans.[22,25]

7.8 Bioengineered Peptide and Protein Therapy:

Mechanism: investigation of the use of bioengineered peptides and proteins to stimulate nerve regeneration and counteract neuropathic injuries in a specific and targeted manner.[24,25]

7.9 Integration of Telehealth in Diabetic Neuropathy Management:

Mechanism: development of telehealth platforms for continuous monitoring of patients with diabetic neuropathy. This could facilitate rapid intervention in case of changes in the patient's condition and improve remote disease management.[23,24]

7.10 Exploration of Therapy Combinations:

Mechanism: evaluation of the potential benefits of combining conventional therapies with innovative ones to achieve synergies in the treatment of diabetic neuropathy.[23-25,50-52]

8. Conclusions

Diabetic neuropathy is a common and serious complication of diabetes mellitus, affecting the peripheral nervous system and significantly impacting patients' quality of life. In this presentation, we have delved into key aspects of diabetic neuropathy, including its definition and context, prevalence, and its impact on patients.

Studies suggest that Low-Level Laser Therapy (LLLT) may have beneficial effects on diabetic neuropathy symptoms, including pain reduction and improvement in nerve function. Further research is needed to establish the optimal protocol and treatment duration. Results may vary among patients.

Transcutaneous Electrical Nerve Stimulation (TENS) provides a non-invasive

option for pain management, and multiple studies support its effectiveness in diabetic neuropathy. Individual responses may vary, and long-term benefits require further research.

Certain antiepileptic and antidepressant medications, such as gabapentin and amitriptyline, have demonstrated efficacy in reducing neuropathic pain. Side effects may occur, and not all patients respond similarly to these medications.

Stem cell therapy holds enormous potential for regenerating affected nerves. Extensive studies are still needed to assess the safety and long-term effectiveness of this approach.

The integration of Virtual Reality (VR) in pain therapy provides an innovative method for distracting patients and may reduce the perceived intensity of pain. Practical implementation may be limited by costs and the need for specialized equipment.

References:

1. Basem Zaino, Rashika Goel, Sanjana Devaragudi, Ananya Prakash, Yogeshkumar Vaghamashi, Yashendra Sethi, Neil Patel, Nirja Kaka, Diabetic neuropathy: Pathogenesis and evolving principles of management, Disease-a-Month, Volume 69, Issue 9, 2023, 101582, ISSN 0011-5029, https://doi.org/10.1016/j.disamonth.2023.101582.
2. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, Bril V, Russell JW, Viswanathan V. Diabetic neuropathy. Nat Rev Dis Primers. 2019 Jun 13;5(1):42. doi: 10.1038/s41572-019-0097-9. PMID: 31197183; PMCID: PMC7096070.
3. Tabish SA. Is Diabetes Becoming the Biggest Epidemic of the Twenty-first Century? Int J Health Sci (Qassim). 2007 Jul;1(2):V-VIII. PMID: 21475425; PMCID: PMC3068646.
4. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-154. doi: 10.2337/dc16-2042. PMID: 27999003; PMCID: PMC6977405.
5. Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014 Aug;14(8):473. doi: 10.1007/s11910-014-0473-5. PMID: 24954624; PMCID: PMC5084622.
6. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93. doi: 10.2337/dc10-1303. Erratum in: Diabetes Care. 2010 Dec;33(12):2725. PMID: 20876709; PMCID: PMC2945176.
7. Calcutt NA. Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms? Pain. 2020 Sep;161(Suppl 1):S65-S86. doi: 10.1097/j.pain.0000000000001922. PMID: 32999525; PMCID: PMC7521457.
8. Soroku Yagihashi, Shin-Ichiro Yamagishi, Ryuichi Wada, Pathology and pathogenetic mechanisms of diabetic neuropathy: Correlation with clinical signs and symptoms, Diabetes Research and Clinical Practice,Volume 77, Issue 3, Supplement, 2007,Pages S184-S189, ISSN 0168-8227, https://doi.org/10.1016/j.diabres.2007.01.054.
9. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Curr Diab Rep. 2019 Aug 27;19(10):86. doi: 10.1007/s11892-019-1212-8. PMID: 31456118; PMCID: PMC6755905.
10. Carmichael J, Fadavi H, Ishibashi F, Shore AC, Tavakoli M. Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy. Front Endocrinol (Lausanne). 2021 May 26;12:671257. doi: 10.3389/fendo.2021.671257. PMID: 34122344; PMCID: PMC8188984.
11. Mark Davies, Sinead Brophy, Rhys Williams, Ann Taylor; The Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes. Diabetes Care 1 July 2006; 29 (7): 1518–1522. https://doi.org/10.2337/dc05-2228

12. Selvarajah D, Kar D, Khunti K, Davies MJ, Scott AR, Walker J, Tesfaye S (2019) Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol 7(12):938–948. https://doi.org/10.1016/s2213-8587(19)30081-6 - DOI - PubMed
13. Gupta M, Knezevic NN, Abd-Elsayed A, Ray M, Patel K, Chowdhury B. Treatment of Painful Diabetic Neuropathy-A Narrative Review of Pharmacological and Interventional Approaches. Biomedicines. 2021 May 19;9(5):573. doi: 10.3390/biomedicines9050573. PMID: 34069494; PMCID: PMC8161066.
14. Burkey AR, Chen J, Argoff CE, Edgar DR, Petersen EA. Painful Peripheral Neuropathies of the Lower Limbs and/or Lower Extremities Treated with Spinal Cord Stimulation: A Systematic Review with Narrative Synthesis. J Pain Res. 2023 May 18;16:1607-1636. doi: 10.2147/JPR.S403715. PMID: 37229154; PMCID: PMC10202826.
15. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012 Jun;11(6):521-34. doi: 10.1016/S1474-4422(12)70065-0. Epub 2012 May 16. PMID: 22608666; PMCID: PMC4254767.
16. Vas PR, Sharma S, Rayman G. Distal Sensorimotor Neuropathy: Improvements in Diagnosis. Rev Diabet Stud. 2015 Spring-Summer;12(1-2):29-47. doi: 10.1900/RDS.2015.12.29. Epub 2015 Aug 10. PMID: 26676660; PMCID: PMC5397982.
17. Thom SR, Hampton M, Troiano MA, Mirza Z, Malay DS, Shannon S, Jennato NB, Donohue CM, Hoffstad O, Woltereck D, Yang M, Yu K, Bhopale VM, Kovtun S, Margolis DJ. Measurements of CD34+/CD45-dim Stem Cells Predict Healing of Diabetic Neuropathic Wounds. Diabetes. 2016 Feb;65(2):486-97. doi: 10.2337/db15-0517. Epub 2015 Oct 20. PMID: 26487786; PMCID: PMC4747459.
18. Kessler JA, Shaibani A, Sang CN, Christiansen M, Kudrow D, Vinik A, Shin N; VM202 study group. Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clin Transl Sci. 2021 May;14(3):1176-1184. doi: 10.1111/cts.12977. Epub 2021 Feb 2. PMID: 33465273; PMCID: PMC8212761.
19. Guedon JM, Wu S, Zheng X, Churchill CC, Glorioso JC, Liu CH, Liu S, Vulchanova L, Bekker A, Tao YX, Kinchington PR, Goins WF, Fairbanks CA, Hao S. Current gene therapy using viral vectors for chronic pain. Mol Pain. 2015 May 13;11:27. doi: 10.1186/s12990-015-0018-1. PMID: 25962909; PMCID: PMC4446851.
20. Iordache C, Antohe M-E, Chirieac R, Ancuța E, Țănculescu O, Ancuța C. Volumetric Cone Beam Computed Tomography for the Assessment of Oral Manifestations in Systemic Sclerosis: Data from an EUSTAR Cohort. Journal of Clinical Medicine. 2019;
21. Gradinaru I ., Jipu R. , Hurjui L.L. , Pendefunda A.A.C. Armencia, A.O. ,Mitrea, M. ,Antohe, M.E. , Current aspect of metal-ceramic-biomaterial restorations and technology , Romanian Journal Of Oral Rehabilitation, 2020, 12 (2) , pp.116-127
22. Forna N.C., Dascalu C. , Forna D ., Antohe M.E. , Incidence and prevalence of dental - periodontal conditions and edentation in Moldavia, Medical-Surgical Journal-Revista Medico-Chirurgicala , 2013,117 (1) , pp.205-211
23. Bolat, M. Nicolae, B.D. , Baciu, E.R. , Forna, D.A., Bosinceanu, D.G. ,Forna, N.C. , Partial Dentures-Succeses and Failures, Oct-dec 2017 ,Romanian Journal of Oral Rehabilitation 9 (4) , pp.93-96
24. Martu M.A., Solomon S.M. , Toma V. , Maftei G.A. , Iovan, A. Gamen A. , Hurjui, L. , Rezus, E. , Foia L. Forna N.C. , The importance of cytokines in periodontal disease and rheumatoid arthritis. review,Romanian Journal Of Oral Rehabilitation,2019, 11 (2) , pp.230-240
25. 25.Puisoru, M., Forna, N., Fatu, A.M. Fatu, R., Fatu, C. , Analysis of mandibular variability in humans of different geographic areas, Annals of anatomy-Anatomischer Anzeiger,Volume 188,Issue 6, 2006, Page. 547-554
26. Leca, D. ,Calin, A.M., Earar, K. ,Nechita, A. , Chiscop, I., Dorobat, G. , Dorobat, C. , Ilie, M., Debita, M ., Biochemical Changes of Cerebrospinal Liquid in Viral Meningitis, Revista de chimie, 2015, 66 (12) , pp.2005-2008
27. Bhandari R, Sharma A, Kuhad A. Novel Nanotechnological Approaches for Targeting Dorsal Root Ganglion (DRG) in Mitigating Diabetic Neuropathic Pain (DNP). Front Endocrinol (Lausanne). 2022 Feb 8;12:790747. doi: 10.3389/fendo.2021.790747. PMID: 35211091; PMCID: PMC8862660.

28. A. Rastogi, E.B. Jude, Novel treatment modalities for painful diabetic neuropathy,Diabetes & Metabolic Syndrome: Clinical Research & Reviews,Volume 15, Issue 1,2021,Pages 287-293,ISSN 1871-4021,https://doi.org/10.1016/j.dsx.2021.01.004.
29. Coman, M., Chiscop, I , Matei, MN , Ghibu, L , Miftode, E , Dorobat, C , Nechita, A , Earar, K , Ilie, M , Moisei, M ., Leca, D ., Dynamics of Biochemical Changes in Viral B Virus Hepatitis, Revista de chimie , 2015, 66 (12) , pp.2144-2146
30. Esanu, I., Debita, M , Dorobat, CM , Iliescu, AA , Matei, MN , Palade, DO Earar, K , Chemical and Biological Factors in Infectious Diseases The oral microbial flora, Revista de chimie ,2019, 70 (4) , pp.1420-142
31. Toma, V., Cioloca, D.P. ,Forna, D.A., Hurjui, L., Botnariu, G.I. Nechifor, I.E. , Bogdan, M. , Costuleanu, M. ,Simion, L., Holban, C., IL 18 as an Important Gingival Inflammatory Biochemical Marker in Children and Adolescents with Insulin-Dependent Diabetes Mellitus, Revista De Chimie, 2016, 67 (12) , pp.2545-2551
32. Ciurcanu, O.E., Forna, D.A., Popa, C. , Scutariu, M.M. , Implementation of methods of loco-regional anesthesia in dental surgery, Oct-dec 2017 ,Romanian Journal Of Oral Rehabilitation, 9 (4) , pp.120-127
33. Jensen TS, Karlsson P, Gylfadottir SS, Andersen ST, Bennett DL, Tankisi H, Finnerup NB, Terkelsen AJ, Khan K, Themistocleous AC, Kristensen AG, Itani M, Sindrup SH, Andersen H, Charles M, Feldman EL, Callaghan BC. Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. Brain. 2021 Jul 28;144(6):1632-1645. doi: 10.1093/brain/awab079. PMID: 33711103; PMCID: PMC8320269.
34. Pang L, Lian X, Liu H, Zhang Y, Li Q, Cai Y, Ma H, Yu X. Understanding Diabetic Neuropathy: Focus on Oxidative Stress. Oxid Med Cell Longev. 2020 Jul 31;2020:9524635. doi: 10.1155/2020/9524635. PMID: 32832011; PMCID: PMC7422494.
35. Puscu D.C. , Ciuluvica R.C. , Anghel A., Malaescu G.D. , Ciursas A.N. , Popa G.V., Forna D.A. ,Busuioc C.J ., Silosi, I. , Periodontal disease in diabetic patients - clinical and histopathological aspects, 2016, Romanian Journal Of Morphology And Embryology 57 (4) , pp.1323-1329
36. Patrascu A., Savin L., Mihailescu D., Mihailescu D.,Grigorescu V. Grierosu C., ,Nicoleta Mihai D., Stana A.H., Botez P., Epidemiological study of femoral head osteonecrosis, Revista de ChimieVolume 68, Issue 5, Pages 974 – 9762017
37. Dobre, C, Duceac, L, Grierosu, C, ; Mihai, D ; Zaharia, A ; Stafie, L; Stadoleanu, C, Efficient Measures for burnout prevention in palliative care, IJMD, Volume21, Issue2, Page81-84, 2017
38. Forna N., Dabija M.G., Damir D., Duceac L., Gabriela C., Ichim D.L., Guțu C., Grierosu C., Eva L.,, Ciuhodaru M.I., Goroftei ERB, Banu E.A., Stafie L., Ciolpan G., Marcu C., Nano-Architectonics of Antibiotic-Loaded Polymer Particles as Vehicles for Active Molecules, Materials, 2021
39. Savin, L., Lupescu, O., Patrascu, A., Grierosu, C., Botez, P., Implanting the prosthetic components based on radiologic planning in deformities of the knee in valgus, Materiale Plastice, 2017, 54(1), pp. 79–82
40. Patrascu, A., Lupescu, O., Savin, L., Grigorescu, V., Botez, P., Tranexamic acid vs autologous reinfusion drain in primary HIP arthroplasty a retrospective cohort study, Revista de Chimie, 2016, 67(11), pp. 2210–2213
41. Marciuc, EA , Dobrovat, BI , Popescu, RM , Dobrin, N , Chiriac, A , Marciuc, D , Eva, L , Haba, D , 3D Printed Models-A Useful Tool in Endovascular Treatment of Intracranial Aneurysms, May 2021, Brain Sciences 11 (5)
42. Simionescu N. , Nemecz M. , Petrovici, A.R. ,Nechifor, I.S. Buga, R.C. , Dabija, M.G. , Eva L .,Georgescu, A., Microvesicles and Microvesicle-Associated microRNAs Reflect Glioblastoma Regression: Microvesicle-Associated miR-625-5p Has Biomarker Potential,International journal of molecular sciences, 2022, 23 (15)
43. Ancuta C., Ancuta E., Iordache C., Ceausu M., Chirieac R., Immunohistochemical study of skeletal muscle in rheumatoid myositis, Romanian Journal of Morphology and Embryology (RJME) 2009, 50 (2):223-227
44. Maftei G.A. , Martu M.A. , Martu M.C. , Popescu D. , Surlin P. , Tatarciuc D. , Popa C. , Foia L.G.,Correlations between Salivary Immuno-Biochemical Markers and HbA1c in Type 2 Diabetes Subjects before and after Dental Extraction,Antioxidants, 2021, 10 (11)
45. Vlad C.E , Foia L., Popescu R., Ivanov I., Luca M.C. ,Delianu C. , Toma V. , Statescu C., Rezus C . Florea L. , Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease, Journal of diabetes research, 2019

46. Ancuța C., Ancuța E., Chirieac R., Anton C., Iordache C., TNF Inhibitors and Periodontal Inflammation in Psoriatic Arthritis, Revista de chimie, 2017, 68 (8), 1914-1918,
47. Haba D., Teslaru S., Hodorog D, Zetu L., Ancuţa, C., Iordache C., Evaluation of serum and gingival crevicular fluid, C reactive protein and IL-6 levels in patients with periodontitis and transient ischemic attaacks" Rom J Morphol Embryol (RJME) 2011, 52(4):1243–1247
48. Pavel L.L. , Tiutiuca, C., Berbece, S.I. , Condratovici A.P. , Ioanid, N., Chemical Physiology of Muscle Contraction, Revista De Chimie, 2017, 68 (5) , pp.1095-1097
49. Iordache, C., Fatu, AM , Pomârleanu, C ., Scurtu, D., Ancuta, C ., Temporomandibular Joint In Juvenile Idiopathic Artritis: An Imaging Study And Ergonomic Considerations,, Romanian Journal Of Oral Rehabilitation, 2017, 9(1), Page : 60-67
50. Scripcaru A., Forna N., Ciubara A.B. ,Benea, H.R.C. , Veringa V ., Sirbu M.T. ,Tudor R. , Sirbu P.D. , The Advantages of Bioresorbable INION® Implants in Traumatology Design, polymer composition and preliminary results,Materiale plastice 56 (1) , pp.47-50
51. Mattia Albiero, Angelo Avogaro, Gian Paolo Fadini, Restoring stem cell mobilization to promote vascular repair in diabetes, Vascular Pharmacology,Volume 58, Issue 4,2013,Pages 253-258,ISSN 1537-1891,https://doi.org/10.1016/j.vph.2013.01.003.
52. Schreiber AK, Nones CF, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: Physiopathology and treatment. World J Diabetes. 2015 Apr 15;6(3):432-44. doi: 10.4239/wjd.v6.i3.432. PMID: 25897354; PMCID: PMC4398900.